Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

Amgen Earnings Call Highlights Growth Engines, Tax Risk

📈 Amgen reported Q1 earnings with a cautiously upbeat tone, highlighting solid commercial momentum and upgraded revenue guidance.

💊 Growth engines now dominate the portfolio, with six key drivers generating roughly 70% of product sales and growing 24% year over year.

💰 Total product sales increased 4%, underpinned by breadth as 16 products posted double-digit growth and 17 annualized above $1 billion.

🩺 Repatha led revenue with Q1 sales of $876 million, up 34%, bolstered by new data showing a 31% reduction in major cardiovascular events for high-risk patients.

🦴 Evenity delivered strong growth with 27% year-over-year sales to $562 million, capturing about 65% of the U.S. bone builder market.

💉 Rare disease assets accelerated with a 25% portfolio growth to $1.2 billion, driven by Eplisna tripling in sales and TEPEZZA rising 29%.

🎯 Oncology and biosimilars delivered double-digit gains, with innovative oncology up 25% to $1.8 billion and biosimilars growing 14% to $835 million.

📊 Amgen upgraded its 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS guidance to $21.70–$23.10 based on strong free cash flow of $1.5 billion.

🔬 R&D spending climbed 16% year over year, supported by AI efficiencies that have halved antibody optimization timelines and streamlined regulatory documentation.

🏭 Capital expenditures reached $700 million in Q1, with roughly $2.6 billion planned for the year to expand manufacturing capacity for late-stage assets.

⚠️ Legacy osteoporosis products face accelerated erosion through 2026 as combined Prolia and XGEVA sales declined 32% to $1.1 billion due to biosimilar competition.

💸 Non-GAAP cost of sales rose to 19.5% of product sales, driven by higher royalty obligations and evolving product mix, creating near-term margin pressure.

⚖️ Regulatory and clinical setbacks included a proposed FDA withdrawal for Tabneos, trial pauses for blinatumomab, and the discontinuation of AMG 193 development.

🏛️ Amgen disclosed receipt of a draft IRS Notice of Proposed Adjustment challenging profit allocations for 2016–2018, introducing significant tax risk to future earnings.

Bullish Signals
  • Amgen reported modest 4% overall sales growth driven by high-growth franchises, effectively cushioning the blow from drugs facing loss of exclusivity.
  • Six key growth drivers generated roughly 70% of Amgen's product sales in the first quarter and grew 24% year over year, demonstrating a structural advantage as older products decline.
  • Repatha stood out with first-quarter sales of $876 million, up 34% year over year, bolstered by new data showing a 31% reduction in major cardiovascular events in high-risk diabetes patients.
  • Evenity delivered 27% year-over-year sales growth to $562 million, including 35% growth in the U.S. where it now holds about 65% of the bone-builder market.
  • Amgen's rare disease portfolio grew 25% to $1.2 billion, with TEPEZZA's U.S. sales rising 29% to $490 million and Eplisna sales nearly tripling to $262 million.
  • The innovative oncology portfolio posted 25% growth to $1.8 billion, while biosimilars remained a growth pillar with sales up 14% to $835 million.
  • Management raised 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS guidance to $21.70–$23.10, reflecting confidence in the upgraded outlook.
  • Non-GAAP R&D spending climbed 16% year over year with AI initiatives that have roughly halved antibody lead-optimization timelines and tripled clinical site enrollment rates.
  • Capital expenditures reached $700 million in the quarter, with roughly $2.6 billion planned for the year to expand manufacturing capacity, including preparations for a potential Meritide launch.
Risk Factors
  • Total sales growth was modest at only 4%, while legacy products like Prolia and XGEVA suffered a 32% decline to $1.1 billion in Q1 due to biosimilar competition, signaling significant revenue erosion risks.
  • The FDA has proposed withdrawing approval for Tabneos and paused enrollment for blinatumomab and SLE trials due to inflammatory events, while development of AMG 193 was discontinued entirely, representing direct pipeline attrition.
  • Amgen faces a substantial tax risk as it received a draft IRS Notice of Proposed Adjustment for 2016–2018 challenging profit allocations, which could materially impact future earnings if finalized.
  • Non-GAAP cost of sales rose to 19.5% of product sales due to increased royalty obligations and product mix shifts, with management warning these margin pressures are unlikely to ease in the near term.
  • Capital expenditures for the year are projected at approximately $2.6 billion to expand manufacturing capacity and prepare for potential Meritide launches, placing significant financial strain on operations.
  • Rising costs and unresolved tax disputes continue to act as headwinds despite AI-enabled R&D gains and solid cash generation, limiting immediate upside to profitability metrics.
  • Accelerated sales erosion of older osteoporosis brands is expected to continue through 2026 as multiple biosimilars enter the market, creating pressure on overall portfolio growth.
Full Analysis
Amgen Inc (AMGN) held its Q1 earnings call with management emphasizing solid commercial momentum, upgraded guidance, and a strengthening late-stage pipeline despite visible headwinds. The company reported modest 4% overall sales growth in the first quarter, which was powered by high-growth franchises that grew 24% year over year while legacy products faced decline due to loss of exclusivity and biosimilar competition. Total product sales were underpinned by breadth rather than dependence on any single blockbuster, with sixteen products posting double-digit growth and seventeen annualizing above $1 billion in sales. Key drivers included Repatha, which saw first-quarter sales of $876 million (up 34% year over year), and Evenity, which grew 27% to $562 million as it captured roughly 65% of the U.S. bone-builder market. The rare disease portfolio grew 25% to $1.2 billion, led by Eplisna sales nearly tripling to $262 million and TEPEZZA's U.S. sales rising 29% to $490 million. Innovative oncology posted 25% growth to $1.8 billion, while biosimilars remained a pillar with sales up 14% to $835 million. Financial strength was underscored by a non-GAAP operating margin of 45%, $1.5 billion in free cash flow, and an upgrade to 2026 revenue guidance of $37.1–$38.5 billion with non-GAAP EPS guidance of $21.70–$23.10. Management highlighted significant investments in R&D and manufacturing, with non-GAAP R&D spending climbing 16% and capital expenditures reaching $700 million in the quarter, totaling roughly $2.6 billion planned for the year to expand capacity. Pipeline advances include Meritide progressing through multiple Phase III trials and olpasiran continuing in Phase III with more than 95% reductions in Lp(a). AI initiatives are reported to have halved antibody lead-optimization timelines and tripled clinical site enrollment rates, while also reducing production line clearance time significantly. However, challenges remain including steep erosion of older osteoporosis brands like Prolia and XGEVA, which combined sales dropped 32% to $1.1 billion in the quarter due to biosimilars entering the market. Cost of sales rose to 19.5% of product sales driven by higher profit-share and royalty obligations, with management warning that these pressures are unlikely to ease near term. Regulatory friction includes a proposed FDA withdrawal of approval for Tabneos and paused enrollment for blinatumomab trials due to inflammatory events, alongside the discontinuation of development for AMG 193. Additionally, Amgen disclosed receipt of a draft IRS Notice of Proposed Adjustment challenging profit allocations for 2016–2018, introducing potential tax risk that could impact future financial outcomes.